Endocrine Abstracts

Introduction: Nivolumab is an anti-programmed cell death-1 monoclonal antibody approved for the treatment of metastatic malignant melanoma. Several endocrine disorders have been reported as immune-related adverse effects. However, nivolumab-induced hypophysitis has a lower incidence than ipililumab.Case report: A 69-years old man with metastatic melanoma started to receive nivolumab. Ten weeks after the first cycle of nivolumab he presented hyperthyroidi...